Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
H.R. 6446; childhood nutrition issues;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Issues related to corporate tax, including tax reform.
Financial services
Duration: January 1, 2008
to
December 31, 2012
General Issues: Health Issues , Taxation/Internal Revenue Code , Financial Institutions/Investments/Securities , Budget/Appropriations , Food Industry (Safety, Labeling, etc.) , Medicare/Medicaid , Trade (Domestic & Foreign)
Spending: about $840,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Karina Lynch Senate Committees on Aging and Gov. Affairs
Staff, Senate Special Committee on Aging
Susan Hirschmann COS, Rep.Van Hilleary and Majority Whip DeLay
Christopher Hatcher Sch. C, Treasury. ; LD, Rep. Scott McInnis
Staff Asst.; Special Asst,; & Leg. Manger, Treasury
Becky Anderson White House Office of Legislative Affairs
Joel Oswald Prof. Staff, Senate Banking; LA, Sen. Enzi
Prof.Staff,, Senate Banking; LA,Sen.Enzi.
Michael Beer LA, Rep. Dave Hobson
Karina Lynch continued Staff, Senate Committe on Government Affairs
Staff, Senate Committee on Government Affairs
Christopher Hatcher continued LD, Rep. Scott McInnis
KARINA V. LYNCH n/a
GEORGE G. OLSEN n/a
Robert E. Glennon n/a
George Olsen n/a
J.Steven Hart n/a
Erin Book n/a
Matthew Hoekstra n/a
J. Steven Hart n/a
Jenny DiJames n/a
Karina Lynch Lynch n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2013
Williams & Jensen, PLLC. terminated an engagement in which they represented ABBOTT LABORATORIES on April 22, 2013.
Original Filing: 300559706.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
H.R. 6446; childhood nutrition issues;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
4th Quarter, 2012
In Q4, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532782.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
H.R. 6446; childhood nutrition issues;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
3rd Quarter, 2012
In Q3, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511625.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
H.R. 6446; childhood nutrition issues;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
2nd Quarter, 2012
In Q2, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300490974.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Reauthroization of the Prescription Drug User Fee Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
1st Quarter, 2012
In Q1, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on April 20, 2012.
Original Filing: 300470060.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues;
General health care reform (Patient Protection and Affordable Care Act).
Reauthroization of the Prescription Drug User Fee Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
4th Quarter, 2011
In Q4, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300449579.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues; Deficit Commission; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2012 Administration budget proposal. Tax extenders.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety.
Child nutrition.
Type of Issue
Food Industry (Safety, Labeling, etc.)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
3rd Quarter, 2011
In Q3, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300428300.xml
Lobbying Issues
Drug safety; Drug importation; authorized generics; drug company settlements; Preserve Access to Affordable Generics Act;
Federal preemption for drugs and devices; Medical device safety;
Prescription drug advertising;
Congressional oversight issues; Deficit Commission; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals. Tax extenders.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety.
Child nutrition.
Type of Issue
Food Industry (Safety, Labeling, etc.)
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Financial Institutions/Investments/Securities
2nd Quarter, 2011
In Q2, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300405572.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization.
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Prescription drug advertising;
Congressional oversight issues; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2012 Administration Budget proposal. Tax extenders.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety including H.R. 2749, Food Safety Enhancement Act of 2009 and S. 510, the FDA Food Safety Modernization Act.
Child nutrition
Type of Issue
Food Industry (Safety, Labeling, etc.)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on April 20, 2011.
Original Filing: 300374762.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; FDA-PDUFA reauthorization.
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Prescription drug advertising;
Congressional oversight issues; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2011 Administration Budget proposal. Tax extenders, S. 3793. H.R. 4853.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety including H.R. 2749, Food Safety Enhancement Act of 2009 and S. 510, the FDA Food Safety Modernization Act.
Child nutrition
Type of Issue
Food Industry (Safety, Labeling, etc.)
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300350393.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Prescription drug advertising;
Congressional oversight issues; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2011 Administration Budget proposal. Tax extenders, S. 3793. H.R. 4853.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety including H.R. 2749, Food Safety Enhancement Act of 2009 and S. 510, the FDA Food Safety Modernization Act.
Child nutrition, S. 3306 and H.R. 5504.
Type of Issue
Food Industry (Safety, Labeling, etc.)
3rd Quarter, 2010
In Q3, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on Oct. 20, 2010.
Original Filing: 300324918.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; and FY 2011 Financial Services and General Government Appropriations bill;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Prescription drug advertising;
Congressional oversight issues; and
General health care reform (Patient Protection and Affordable Care Act).
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2011 Administration Budget proposal. Tax extenders, S. 3793.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety including H.R. 2749, Food Safety Enhancement Act of 2009 and S. 510, the FDA Food Safety Modernization Act.
Child nutrition, S. 3306 and H.R. 5504.
Type of Issue
Food Industry (Safety, Labeling, etc.)
2nd Quarter, 2010
In Q2, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on July 20, 2010.
Original Filing: 300296903.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Prescription drug advertising; and
Congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2011 Administration Budget proposal
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Food and safety including H.R. 2749, Food Safety Enhancement Act of 2009 and S. 510, the FDA Food Safety Modernization Act.
Type of Issue
Food Industry (Safety, Labeling, etc.)
1st Quarter, 2010
In Q1, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $50,000. The report was filed on April 20, 2010.
Original Filing: 300268343.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act;
Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Comparative effectiveness including S. 1213, Patient-Centered Outcomes Research Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Prescription drug advertising; ESRD payments; and
congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Medicare drug payment and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act; H.R. 4872, the Health Care and Education Reconciliation Act of 2010.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2011 Administration Budget proposal
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on Jan. 20, 2010.
Original Filing: 300241094.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009;
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act; H.R. 3962, Affordable Health Care for America Act; H.R. 3590, Patient Protection and Affordable Care Act;
Prescription drug advertising;
Bisphenol A including S. 593; and
congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug payment and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2010 Administration Budget proposal
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on Oct. 20, 2009.
Original Filing: 300216961.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009;
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Health care reform including H.R. 3200, America's Affordable Health Choices Act; Affordable Health Choices Act; and America's Healthy Future Act;
Prescription drug advertising;
Bisphenol A including S. 593; and
congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug payment and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2010 Administration Budget proposal
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
In Q2, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on July 16, 2009.
Original Filing: 300180791.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009;
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act; S. 1213, Patient-Centered Outcomes Research Act of 2009;
Health information technology including the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Health care reform; including the Affordable Health Choices Act ;
Prescription drug advertising;
Bisphenol A including S. 593; and
congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug payment and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to corporate tax, including international tax proposals in FY 2010 Administration Budget proposal
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2009
In Q1, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on April 16, 2009.
Original Filing: 300150996.xml
Lobbying Issues
Drug safety including H.R. 579, the Food and Drug Administration Globalization Act; Drug importation including S. 525/H.R. 1298, the Pharmaceutical Market Access and Drug Safety Act of 2009;
Follow-on biologics including H.R. 1548, the Pathway to Biosimilars Act; S. 726/H.R. 1427, Promoting Innovation and Access to Life-Saving Medicines Act;
Physician payment disclosure legislation including S. 301, Physician Payments Sunshine Act of 2009;
Comparative effectiveness including H.R. 1, the American Recovery and Reinvestment Act;
Health information technology including the American Recovery and Reinvestment Act;
Authorized generics including H.R. 573; S. 501, Fair Prescription Drug Competition Act;
Drug company settlements including S. 369, Preserve Access to Affordable Generics Act; H.R. 1706, Protecting Consumer Access to Generic Drugs Act;
Federal preemption for drugs and devices including H.R. 1346/S. 540, Medical Device Safety Act of 2009;
Health care reform;
Prescription drug advertising;
Bisphenol A including S. 593; and
congressional oversight issues.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicaid drug rebates including S. 547/H.R. 904, Drug Rebate Equalization Act of 2009; H.R. 1725, Voluntary State Discount Prescription Drug Plan Act of 2009; Medicare drug payment and coverage including S. 330/H.R. 684, Medicare Prescription Drug Savings and Choice Act of 2009; S. 266, Medicare Prescription Drug Gap Reduction Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation related to corporate taxation issues including H.R. 1, the American Recovery and Reinvestment Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2008
In Q4, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on Jan. 18, 2009.
Original Filing: 300125617.xml
Lobbying Issues
Prescription Drug User Fees; Drug Safety/Clinical Trials; Pediatric Trials and Studies; Drug Importation and Counterfeiting;
Follow-On Biologics; Drug Advertising; Medicare/Medicaid Drug Coverage and Payment; Drug Price Negotations; Stents; Physician Payment Sunshine legislation; Preemption, BPA; and Health Care Reform.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare drug rebate; Medicare drug price negotiation; Medicare drug coverage and payment.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation related to corporate taxation issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2008
In Q3, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on Oct. 20, 2008.
Original Filing: 300104503.xml
Lobbying Issues
Prescription Drug User Fees; Drug Safety/Clinical Trials; Pediatric Trials and Studies; Drug Importation and Counterfeiting;
Follow-On Biologics; Drug Advertising; Medicare/Medicaid Drug Coverage and Payment; Drug Price Negotations; Stents; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare drug rebate; Medicare drug price negotiation; Medicare drug coverage and payment.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation impacting intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2008
In Q2, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on July 17, 2008.
Original Filing: 300069629.xml
Lobbying Issues
Prescription Drug User Fees; Drug Safety/Clinical Trials; Pediatric Trials and Studies; Drug Importation and Counterfeiting;
Follow-On Biologics; Drug Advertising; Medicare/Medicaid Drug Coverage and Payment; Drug Price Negotations; Stents; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare drug rebate; Medicare drug price negotiation; Medicare drug coverage and payment.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislation impacting intellectual property issues.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2008
In Q1, Williams & Jensen, PLLC. lobbied for ABBOTT LABORATORIES , earning $30,000. The report was filed on April 21, 2008.
Original Filing: 300049202.xml
Lobbying Issues
Prescription Drug User Fees; Drug Safety/Clinical Trials; Pediatric Trials and Studies; Drug Importation and Counterfeiting;
Follow-On Biologics; Drug Advertising; Medicare/Medicaid Drug Coverage and Payment; Drug Price Negotations; Stents; S. 2029.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare drug rebate; Medicare drug price negotiation; Medicare drug coverage and payment.
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...